Humasis Co. Ltd. (KOSDAQ:205470)

-13.56% (1Y)

Market Cap	175.95B
Revenue (ttm)	29.71B
Net Income (ttm)	-33.78B
Shares Out	113.15M
EPS (ttm)	-296.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,926,124
Average Volume	14,007,081
Open	1,564.00
Previous Close	1,553.00
Day's Range	1,540.00 - 1,634.00
52-Week Range	1,254.00 - 3,235.00
Beta	0.38
RSI	50.06
Earnings Date	Aug 14, 2025

About Humasis

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women’s health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the quali...

• Industry: Medical - Equipment & Services
• Sector: Healthcare
• Founded: 2000
• Employees: 70
• Stock Exchange: KOSDAQ
• Ticker Symbol: 205470

Financial Performance

In 2024, Humasis's revenue was 25.41 billion, an increase of 83.79% compared to the previous year's 13.83 billion. Losses were -30.44 billion, -45.08% less than in 2023.